You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
耀才團隊: 市場轉為關注中國CPI及PPI
阿思達克 12-09 11:00
耀才證券研究部團隊稱,隔晚(8日)美股三大指數全線向上,並一同創出紀錄新高,英國啟動新冠肺炎疫苗大規模施打計畫,為全球首次採用輝瑞(PFE.US)及BionTech(BNTX.US)的疫苗;道指高見30,246點創歷史新高;納指連升第四日,收報12,582點創收市新高;標指收跌7點;標普500指數亦創新高,收報3,702點。港股ADR及黑期預示恆指將反彈過百點,但仍可能受制於20天線,中國與美澳關係緊張,市場將焦點轉為內地經濟數據,市場預計CPI按年升幅持平,PPI則按年下跌1.8%。

京東健康(06618.HK)昨日首掛表現亮麗,MSCI將把其納入MSCI標準指數及大盤股指數,本月22日起生效,而富時羅素的富時香港指數亦會納入京東健康,本月21日起生效,將會有更多被動資金追入。

從技術上看,恆指短線跌穿即市支持20天線,該水平同時為保力加通道之中軸,假若未能修復該水平恆指將下試通道底部26,132點,即需要修補11月16號造成的上升裂口。如果成功重反20天線,即有望於27,000點前作上落格局。

(筆者為證監會持牌人)~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account